AZD4117 + AZD5315 Vaccines for Flu
(PANDA Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests two new vaccines, AZD4117 and AZD5315, designed to protect against certain bird flu strains, specifically H5N1 and H7N9. The main goal is to determine the safety of these vaccines and their ability to trigger an immune response. Participants will be divided into groups to receive varying doses of the vaccines or a placebo, a harmless substance used for comparison. Individuals who have been medically stable for the past three months may be suitable for this trial. As a Phase 1 and Phase 2 trial, this research aims to understand how the vaccines work in people and measure their effectiveness in an initial, smaller group, offering participants a chance to contribute to groundbreaking medical advancements.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, if you are on immune-modifying drugs, immunosuppressive therapy, or long-term systemic corticosteroids, you may not be eligible to participate.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research shows that AZD4117 and AZD5315 are being tested for safety and effectiveness against certain bird flu strains. Other studies have found that flu vaccines are generally well-tolerated, with serious side effects occurring in about 1-2 cases per million doses.
Specific safety data for these two vaccines is not yet available, but their presence in early testing suggests they are considered safe enough for human trials at this stage. This likely indicates they have passed initial safety tests in labs and on animals.
In summary, although detailed safety information for AZD4117 and AZD5315 is not yet available, ongoing studies aim to confirm their safety for people. Participation in these trials will help gather important information about human responses to these vaccines.12345Why are researchers excited about this trial's treatments?
Researchers are excited about AZD4117 and AZD5315 vaccines for flu because they offer new approaches to flu prevention compared to traditional vaccines. Unlike standard flu vaccines that often rely on inactivated or live attenuated viruses, these treatments may utilize advanced adjuvant systems or novel antigens to boost immune response. This could lead to enhanced protection, particularly in older adults who typically have weaker immune responses to conventional vaccines. Additionally, these vaccines might offer broader protection against multiple flu strains, reducing the need for annual updates.
What evidence suggests that this trial's vaccines could be effective against avian Influenza A?
This trial will evaluate the effectiveness of two vaccines, AZD4117 and AZD5315, in preventing flu infections. Studies have shown that vaccines like AZD4117 can greatly reduce the risk of flu. In one study, only 2.2% of those who received the vaccine got sick, compared to 7.1% of those who received a placebo, demonstrating that AZD4117 is 69% effective in preventing flu infections. Meanwhile, researchers are studying AZD5315 for its ability to protect against certain flu strains. Both vaccines strengthen the body's immune system to fight the flu, especially targeting bird flu strains like H5N1 and H7N9. Early research suggests they could be promising in lowering the risk of flu. Participants in this trial will receive either AZD4117 or AZD5315, with different dosage levels tested across various age groups.13678
Are You a Good Fit for This Trial?
This trial is for adults over 18 who are medically stable, meaning no hospital stays or major treatment changes in the last 3 months. It's not for those with certain heart conditions, nerve disorders, allergies to vaccine ingredients, recent blood product recipients, or participants in other trials. Pregnant women and those not using effective birth control are excluded.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either AZD4117, AZD5315, or placebo to assess safety and immunogenicity
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- AZD4117
- AZD5315
Find a Clinic Near You
Who Is Running the Clinical Trial?
AstraZeneca
Lead Sponsor
Sir Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Dr. Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology
Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Medical Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology
Biomedical Advanced Research and Development Authority
Collaborator
Joint Program Executive Office (JPEO) Chemical, Biological, Radiological, and Nuclear Defense (CBRND) Enabling Biotechnologies (EB)
Collaborator